Business ❯Corporate Governance ❯Executive Accountability
Shareholder Rights Financial Reporting Disclosure Obligations Class Action Lawsuits Market Impact Market Communications Public Companies Economic Loss Recovery Financial Disclosure Securities Violations Legal Compliance
The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.
